KR20200041659A - Composition for prevention or treatment of oral disease - Google Patents

Abstract

The present invention relates to an oral hygiene composition for preventing or alleviating oral diseases containing any one or more of eugenol and hinokitiol, and carbazochrome as active components. According to the present invention, it is possible to provide a useful use of novel active components which have less side effects, are safe to the human body, and also can inhibit the growth of bacteria in the oral cavity. In addition, the present invention provides a composition containing active components excellent in the efficacy as active components, particularly provides an oral care composition for preventing or alleviating dental caries, periodontal disease, or bad breath.

Description

Composition for prevention or treatment of oral disease

The present invention relates to a composition for oral care, and relates to a composition that is effective in the prevention, improvement or treatment of various oral diseases such as dental caries, periodontal disease, bad breath, and syringe while being safe for the human body.

Dental caries and periodontal disease among oral diseases are known to be the main factors causing various clinical symptoms such as pain, chewing dysfunction, periodontal tissue destruction, bad breath and pain, and loss of teeth. The causative factor is increasing.

As a method of inhibiting the proliferation of oral pathogens that cause dental caries, periodontal disease, bad breath, and pain while inhabiting the periodontal bacterial membrane, various types of antimicrobial agents including antibiotics having bactericidal and bacteriostatic action against these bacteria are decayed, periodontal disease , It has been developed as a treatment and suppression of pulp and apical infections.

However, antibiotics have the disadvantage that they can be used only as therapeutic agents because they are difficult to use in the long term because they can induce the appearance and mycorrhosis of resistant bacteria in the oral cavity along with systemic side effects on our body. In addition, antibacterial agents used in oral cleansing agents include raw guinarine, listerine, pyroxide, chlorhexidine, etc. Raw guinarine (Sangquinarine) has an unclear effect on bacteria in the oral cavity and is more unclear about the treatment effect in periodontal disease. Not only does it have a high price but also has a disadvantage in that it is expensive, and Listerine is a main component of alcohol, which has a temporary effect in the oral cavity, but has some bacteriostatic effects, but also has a disadvantage in that it may have a harmful effect on tissues when used for a long time. Pyroxide (Peroxide), which is being added for the whitening effect, has a poisonous effect on bacteria, but at the same time has a poisonous effect on human tissues, and also has safety problems, and sometimes bacteria resistant to pyroxide appear in bacteria. In addition, chlorhexidine (Chlorhexidine) is known to be the best among the known formulations as a preventive and therapeutic agent for periodontal disease in addition to inhibiting plaque formation, but it has a strong irritating and strong side effect. In addition to the problems indicated, there are other disadvantages that can be used for a long period of time for the purpose of treatment or prevention, such as mycosis, which can also cause carcinogenicity, and limited use in pregnant women.

Accordingly, there is a need for an oral hygiene composition that is effective in preventing and improving oral diseases such as dental caries, periodontal disease, bad breath, and syringe without concern for the side effects described above.

1. Korea Patent Publication No. 10-2016-0050108 2. Korean Patent Publication No. 10-2014-0116111 3. Korean Patent Publication No. 10-2007-0073921

The present invention provides a useful use of a new active ingredient that can suppress the growth of bacteria in the oral cavity while having little side effects and being safe for the human body, and a composition comprising the active ingredient having the above-described active ingredient as an active ingredient, particularly dental caries, periodontal disease , It is intended to provide a composition for oral care to prevent or improve bad breath.

In order to achieve the above-mentioned object, the present invention provides an oral hygiene composition for preventing or improving oral diseases comprising at least one of eugenol and hinokithiol and carbazochrome as active ingredients.

In one aspect of the invention, the carbazochrome is characterized in that the carbazochrome sodium sulfonate.

In one aspect of the present invention, the carbazochrome is contained in 0.001 to 0.1% by weight, and any one or more of eugenol and hinokitiol is characterized in that it is included in 0.001 to 0.1% by weight.

In one aspect of the present invention, the oral disease is composed of bad breath, syringitis, dental caries, periodontal disease, gingivitis, periodontitis, pulpitis, stomatitis, oral mucositis, intraoral mucosal ulcer, thrush, squamous lichen and other oral inflammation lesions Characterized in that it is any one or more diseases selected from the group.

In one aspect of the present invention, the composition is characterized in that it has an antibacterial effect on a strain of the genus Streptococcus or a genus of Porphyromonas .

In one aspect of the invention, the Streptococcus (Streptococcus) spp or Pseudomonas (Porphyromonas) in strains with the foreskin is Streptococcus mutans (Streptococcus mutans), Streptococcus sanggwi switch (Streptococcus sanguis), Streptococcus sanggwi varnish (Streptococcus sanguinis ), Streptococcus salivarius subsp. thermophils , and Porphyromonas gingivalis .

The present invention provides a food composition for improving oral hygiene comprising at least one of eugenol and hinokitiol and carbazochrom as active ingredients.

In one aspect of the present invention, the food composition is characterized in that the carbazochrome is contained in 0.001 to 0.1% by weight, and any one or more of eugenol and hinokitiol is contained in 0.001 to 0.1% by weight.

In one aspect of the present invention, the food composition is composed of bad breath, syringis, dental caries, periodontal disease, gingivitis, periodontitis, pulpitis, stomatitis, oral mucositis, intraoral mucosal ulcer, thrush, squamous lichen and other oral inflammation lesions It is characterized by preventing or improving any one or more diseases selected from the group.

The present invention provides a pharmaceutical composition for the prevention, improvement or treatment of oral diseases comprising at least one of eugenol and hinokitiol and carbazochrom as active ingredients.

In one aspect of the present invention, the pharmaceutical composition is characterized in that the carbazochrome is contained in 0.001 to 0.1% by weight, and any one or more of eugenol and hinokitiol is contained in 0.001 to 0.1% by weight.

In one aspect of the invention, the target oral disease of the pharmaceutical composition is bad breath, acute teeth, dental caries, periodontal disease, gingivitis, periodontitis, pulpitis, stomatitis, oral mucositis, intraoral mucosal ulcer, thrush, lichen planus and other oral cavity Characterized in that it is any one or more diseases selected from the group consisting of inflammatory lesions.

The oral hygiene composition comprising at least one of eugenol and hinokithiol of the present invention and carbazochrom as an active ingredient provides an oral disease prevention, improvement or treatment effect, has fewer side effects, is safe for the human body and is safe for human bacteria. Growth can be suppressed, and excellent dental caries, periodontal disease, bad breath prevention or improvement, yet non-toxic and excellent stability can be provided. Therefore, the composition of the present invention may exhibit excellent effects in the prevention and treatment of dental caries.

1 is an experimental result confirming the inhibitory effect of the composition of the present invention on prostaglandin E2.

The present invention for achieving the above object is characterized. Hereinafter, the present invention will be described in detail with reference to the drawings.

Accordingly, the present inventors conducted a study to derive materials that are effective in preventing and improving various oral diseases without concern for the above-mentioned side effects, and as a result, they are safe and safe to use in the body. It was confirmed that a complex composed of at least one of Eugenol and Hinokitiol and Carbazochrome has excellent efficacy against oral diseases.

The present invention provides an oral hygiene composition for the prevention or improvement of oral diseases comprising at least one of eugenol and hinokithiol and carbazochrome as active ingredients.

The eugenol (Eugenol) is a phenylpropene (phenylpropene) having the following formula structure, sperm oil, coniferous oil, cement oil, in a state free of some oil or some esters, mostly separated from natural products. It is a colorless or pale yellow liquid with a strong carnation-like scent, and becomes darker as the storage days pass. It is insoluble in water and soluble in alcohol, ether, chloroform and ethylene glycol.

[Formula 1]

The hinokithiol (Eugenol) is a natural monoterpenoid having the following chemical structure: Cypress, Cypress, Taiwan Cypress, Chamaecyparis taiwanensis Masamune et Suzuki, Thujaplicata D. Don, T. occidentalis L., T. standishii Carr., Thujopsis dolabrata Sieb et Zucc., Libocedrus decurrens Torrey, Cupressus macrocarpa Hartw. Natural tropolone isolated from the phenolic components of essential oils such as cypress and plant and vaccine Juniperus chinensis L. (Vaccine), also called beta-thujaplicin.

[Formula 2]

The carbazochrome is a substance represented by the following structural formula and contains all of its pharmaceutically acceptable salts, and is useful for promoting blood clotting by agglutinating platelets and stopping bleeding from open wounds.

[Formula 3]

The carbazochrome of the present invention may be carbazochrome, carbazochrome sulfonate, carbazochrome sodium sulfonate, preferably carbazochrome sodium sulfonate. have.

In the oral hygiene composition of the present invention, the carbazochrome is included in 0.001 to 0.1% by weight, and any one or more of eugenol and hinokitiol may be included in 0.001 to 0.1% by weight. Specifically, 0.001 to 0.05% by weight of carbazochrome, 0.001 to 0.05% by weight of eugenol or hinokitiol may be included, and more specifically 0.003 to 0.01% by weight of carbazochrome, 0.003 to 0.01% by weight of eugenol or hinokitiol may be included, , More specifically, it may include 0.003 to 0.007% by weight of carbazochrome, 0.003 to 0.007% by weight of eugenol or hinokitiol.

In the oral hygiene composition of the present invention, the content of carbazochrom and one or more of eugenol and hinokitiol may be the same or different, and in different cases, any one of eugenol and hinokitiol compared to the content of carbazochrom The above content may be 50 to 150%.

The oral disease to which the oral hygiene composition of the present invention is applied is a comprehensive concept including various oral diseases, for example, but not limited to, bad breath, pain, dental caries, periodontal disease, gingivitis, periodontitis, pusitis, stomatitis , Oral mucositis, mucosal ulcers in the mouth, thrush, lichen planus and other oral inflammatory lesions. In addition, the oral disease may include various intraoral diseases that may be caused by external physical stimulation, as well as the effects of microorganisms in the oral cavity, and, for example, exposes the ivory tubules due to tooth surface abrasion, indicating hypersensitivity reactions. Syringe may also include symptoms.

As used herein, the term “treatment” is an approach to obtaining beneficial or desirable clinical results, whether detectable or not, which is beneficial or desirable for the purposes of the present invention, whether partial or complete. Regardless of, including, but not limited to, alleviation of symptoms, reduction in disease severity, stabilized (i.e., no worse) condition of disease, delay or slowing of disease progression, improvement or temporary relief and relief of disease condition no. Thus, treatment refers to both therapeutic and prophylactic measures, and the ones that need to be treated include not only the condition that already has the disease, but also the condition where the disease should be prevented. In addition, by administering the pharmaceutical composition of the present invention to the individual can mean any action to improve or improve the symptoms of oral disease.

As used herein, the term "prevention" may mean any act of suppressing or delaying a disease using the composition for oral hygiene. The oral composition may be used in the form of pharmaceutical compositions (including quasi-drug compositions) and food compositions, but is not necessarily limited to these forms.

As used herein, the term "improvement" means that the symptoms of oral diseases as described above are reduced or softened, and can be understood as a broad concept including alleviation, prevention, and treatment.

As used herein, the term "oral" is intended to mean the entire mouth cavity, including the lips, gums (gingiva), hard and soft palate, uvula, palatal tonsils, teeth, inside the cheeks, tongue and tongue papillae. .

As used herein, the term “halt breath” may refer to a symptom of unpleasant odor in the mouth, but is not limited thereto, typically due to volatile sulfur compounds generated by microorganisms in the oral cavity decomposing proteins. An unpleasant smell may be produced in the mouth.

As used herein, the term “syrinii” means, but is not limited to, all phenomena in which sharp, temporary or persistent pain to external stimuli occurs, apart from tooth decay or other pathological causes. The external stimulus usually refers to a temperature stimulus, which usually complains of a symptom of a cold temperature stimulus. In addition to this temperature stimulation, pain may also be caused by stimulation such as drying of the teeth, contact with foreign substances, osmotic pressure through sweet or sour food. It may appear throughout the entire tooth, and may be limited to certain areas, such as the maxilla or mandible, or the right or left side, and may be accompanied by dentin hyperesthesia, caries, and pulp inflammation. As a cause of this symptom, the exposure of the mouth of the ivory tubule may be considered. When enamel or cementite is destroyed and the entrance of the ivory tubules is exposed to the outside, stimulation is transmitted to the pulp by the cell processes, nerves, and dentin of the ivory tubules, and pain can be felt.

As used herein, the term "tooth caries" refers to dental caries that damages the enamel of teeth by acid generated by the decomposition of sugar, starch, etc., by bacteria living in the mouth. The caries can be caused by a variety of causes, for example, plaque, which is a bacterial film formed on the surface of a tooth. When food is consumed, food residues remain in the mouth, and when caries or starch remaining in the mouth is decomposed by bacteria forming the plaque, acid that attacks and damages the enamel on the tooth surface can cause dental caries.

The term "periodic disease", as used herein, is an oral disease that includes gingivitis and periodontitis depending on the degree, also known as a trench mouth. Periodontal disease causes severe gingivitis, can cause bleeding and pus from the gums, severe pain, and often premature loss of teeth. Periodontal disease is more common in developing countries, and in most cases, most of the periodontal disease can be cured by professional cleaning and antibiotic treatment. However, if left untreated, the infection can spread throughout the body, resulting in serious health complications. Symptoms of periodontal disease include sick gums, poor breathing, unpleasant bad breath, fever, bleeding gums at mild pressure, crater-sized thrush between teeth and gums, swelling lymph nodes around the head, neck or chin, gray on the gums Includes membrane, red gums, swelling gums, and pain when eating or swallowing

As used herein, the term “gingivitis” is a disorder defined as inflammation of the gums and characterized by periodontal disease, the structure of which retains the gums, tissues, dental sacs, and teeth in place. It is characterized by the destruction of the ligaments it makes. Gingivitis is one of the first stages of serious periodontal disease. Symptoms of gingivitis include swelling gums, mouth soreness, bright red or purple appearance on the gums, shiny gums, and painless gums, except for touching hands, and bleeding gums.

As used herein, the term "periodontitis" (periodontitis or Pyorrhea alveolaris) is inflammation of the periodontal tissue, including tissue supporting the teeth in the oral cavity. The part included in the periodontal tissue is the periodontal ligament or PDL, which consists of the gingival (gingival tissue), the alveolar bone (sockets) to which the teeth are attached, the cementitious or outer layer of the root, and connective tissue fibers connecting the gums and cementitious to the alveolar bone. Symptoms are described as progressive loss of bone around the tooth that loosens the tooth or loss of the tooth if left unattended. There are various causes for the disease in which bacteria are most common. Periodontitis is considered an advanced form of gum disease because it already involves bone loss in the area. This is the result of neglecting mild gingivitis. Due to bacterial infection, the body reacts negatively and further complications are caused. Periodontitis is one of the leading causes of tooth loss in adults and affects approximately 50% of people over the age of 30. Signs and symptoms appear due to the unstable anchoring of the teeth and the presence of microorganisms. When brushing your teeth with dental floss, biting, chewing, or touching your fingers, the gums often or sometimes bleed or turn red. Gum can also swell or pus from time to time. Individuals with periodontitis have bad breath or poor breathing, and there is a bitter mouth or metal or tin taste that does not go away. Partially, teeth may become sharp as the teeth lengthen due to gingival recession, which can be caused by severe brushing. When an enzyme called collagenase begins to destroy collagen, a person will have a deep sac between the teeth and gums. In the early stages of periodontal disease, only a few signs and symptoms may be noticeable. Radical periodontitis can affect individuals at a younger age and may develop symptoms. Some manifestations can be very mild, while others can be very serious. Signs and symptoms usually progress naturally, especially in chronic periodontitis.

The term "pulpitis", as used herein, is inflammation that occurs in the dimensions of the inside of the teeth in which a large number of nerves and blood vessels are distributed. It means to fall. When inflammatory factors are released in response to harmful stimuli, blood vessels expand and blood flow increases, resulting in tissue edema. In contrast to normal tissue, in the case of pulp, it exists in a limited space surrounded by hard dentin. The end result will be different from other organizations.

As used herein, the term “stomatitis” basically refers to oral inflammation, but more specifically, stomatitis is the mucous lining of the oral cavity that can include the gums, tongue, cheeks, lips, and the bottom or ceiling of the mouth. (mucous lining). There are various types of stomatitis and classification is based on how a person has acquired the disease. There are two types of stomatitis, contact stomatitis and aphthous stomatitis. Contact stomatitis is inflammation of the oral mucosa caused by contact with allergens or stimulants. Aphthous stomatitis (also known as ulcerative stomatitis or aphthous ulcer) has an unknown etiology. Like contact stomatitis, ulcerative stomatitis affects the oral mucosa. Aphthous ulcer is a type of oral ulcer, which is expressed as a painful open sore inside the mouth or upper throat (including the uvula) caused by mucosal destruction. Aphthous stomatitis is also known as Sutton's Disease, especially in the case of major, ascites or recurrent ulcers. Ulcers are shallow, can be described as individual pain, and are usually observed on neglected mucosal membranes. This type of stomatitis, like contact stomatitis, is self-limiting and generally does not cause complications. The typical size of an ulcer can last 1-2 weeks, while larger ulcers can last for several months.

The term "oral mucositis", as used herein, is a clinical condition in the oral cavity characterized by the presence of reduced epithelial thickness, intense erythema and ulcers associated with painful symptom complexes and possible occurrence of infection and bleeding. It is understood to mean, and optionally includes stomatitis and oral mucosal ulcers.

As used herein, "oral mucosal ulcer" is also referred to as stomatitis, but is not limited to oral mucosa (tongue, gums, lips, cheeks inside) due to infection by bacteria, viruses, fungi, etc. Etc.).

As used herein, the term “oral thrush” is a disease in which the fungus Candida albicans grows in an uncontrolled manner in the mouth. Bacteria, known as flora, control the growth of Candida albicans in a healthy body. The thrush has a creamy white paste that covers the tongue, and can spread rapidly to the palate, gums, back of the throat, tonsils, and inside the cheeks. The symptoms of thrush begin with a white paste covering the tongue and the inside of the cheek. As thrush progresses, mild bleeding may occur if the tongue is rubbed or the patient is brushing his teeth. These symptoms can progress very quickly, but thrush can last for months. If thrush lesions spread to the esophagus, the patient may develop additional symptoms such as difficulty swallowing, feeling food in the middle of the throat or chest, and high fever, and the infection can continue to spread through the esophagus.

As used herein, the term “Lichen planus” is often defined as an oral disease that affects the inflamed mouth. Lichen planus is often recognized as a rash that stimulates oral tissue. Although reports of onset are increasing in young patients, most patients have first experience between 45 and 60 years of age. Lichen planus is often associated with the inside of the cheek, but in many cases it appears to affect the entire mouth, including the gums, tongue, and lips, and in rare cases, the throat or esophagus. Lichen planus also occurs as a skin disease on the skin and is often referred to as a squamous lichen to differentiate it from oral lichen planus. Lichen planus is a self contained disease that can last weeks, months, and in some cases years. It is not contagious. This is often mistaken for sexually transmitted diseases because the genital organs are most noticeably affected in the early stages of development. Treatment is difficult because symptoms and outbreaks occur quickly and then disappear (often weeks). Some patients get great relief from cold soaking or bathing and cryotherapy, but most patients require medical treatment to relieve symptoms.

As used herein, the term “other oral inflammatory lesions” is caused by other forms of oral inflammation (mucositis, viral, bacterial, fungal or protozoan infections or due to immune system abnormalities (immunodeficiency, autoimmunity, or allergies). It can be used to treat, including but not limited to, caused oral ulcers. Also included are submucosal fibrosis, chronic debilitating diseases of the mouth characterized by inflammation, and progressive fibrosis of submucosal tissue. This includes glossitis, inflammation of the tongue, or infection.

The oral disease may be caused by bacteria, but is not limited thereto, and may be caused by bacteria such as a strain of the genus Streptococcus and a strain of the genus Porphyromonas .

Therefore, the oral hygiene composition of the present invention is Streptococcus ( Streptococcus ) genus strain or Porphyromonas ( Porphyromonas ) genus strain, more specifically Streptococcus mutans ( Streptococcus mutans ), Streptococcus sanggu ( Streptococcus sanguis ), Streptococcus estrus It may be any one or more selected from the group consisting of Streptococcus sanguinis , Streptococcus salivarius subsp. Thermophils , and Porphyromonas gingivalis .

More preferably, the oral hygiene composition of the present invention may exhibit an antibacterial effect against Streptococcus mutans or Porphyromonas gingivalis bacteria.

The oral hygiene composition, in addition to any one or more of the active ingredients eugenol and hinokitiol and carbazochrom, depending on the formulation, method of use and purpose of use, additional ingredients, pharmaceutically acceptable or nutritionally acceptable suitable carriers, excipients, Diluents or minor ingredients may be further included.

More specifically, the oral hygiene composition is a nutrient, vitamin, electrolyte, flavor, coloring agent, neutralizer, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusting agents, in addition to the active ingredients Stabilizers, preservatives, glycerin, alcohol, carbonic acid used in carbonated beverages and the like may be further included. In addition, the carrier, excipient or diluent is lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, aquisia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline In the group consisting of cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil, dextrin, calcium carbonate, propylene glycol, liquid paraffin, and physiological saline It may be any one or more selected, but is not limited thereto, and any common carrier, excipient, or diluent may be used.

The oral hygiene composition, when pharmaceutical, may further include conventional fillers, extenders, binders, disintegrants, surfactants, anticoagulants, lubricants, wetting agents, fragrances, emulsifiers or preservatives, both oral or parenteral Can be used.

Specifically, solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and such solid preparations include at least one excipient such as starch, calcium carbonate, It is prepared by mixing sucrose, lactose, or gelatin. In addition, lubricants such as magnesium stearate and talc are used in addition to simple excipients. Liquid preparations for oral use include suspensions, intravenous solutions, emulsions, syrups, etc. In addition to commonly used simple diluents, water and liquid paraffin, various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, can be included. .

Examples of the form for parenteral administration include toothpaste, mouthwash, and topical administration (cream, ointment, dressing solution, spray, and other coating agents). As an example of the topical dosage form, the oral hygiene composition containing the active ingredient may be impregnated into a carrier such as gauze made of natural or synthetic fibers.

In the case of the cream or ointment, periodontal disease, gingival disease may be suitable for applying directly to or around the affected area or cavities. In the case of the spray agent, except for the active ingredient, it may be prepared by a conventional spray preparation method, and may be prevented or treated by spray packaging on a compressed container or other spray container and sprayed frequently to the oral disease site. In the case of the dressing solution, except for containing 2-methoxycinnamaldehyde as an active ingredient, it can be prepared by a conventional method for preparing a dressing solution, and used for dressing in oral disease sites or dressing of other bacterial infection sites. Oral disease can be prevented or treated.

In addition, the formulation of the oral hygiene composition of the present invention may be in a preferred form depending on the method of use, and adopts a method known in the art, in particular, to provide rapid, sustained or delayed release of the active ingredient after administration to a mammal. Can be formulated. Examples of specific formulations include warning agents, granules, lotions, linen agents, limonades, powders, syrups, liquids, aerosols, EXTRACTS, elixirs, ointments, fluid extracts, emulsions, suspensions, Premise, acupuncture, tablets, capsules, creams, pills, soft or hard gelatin capsules, and the like.

Further, the oral hygiene composition of the present invention is preferably using a suitable method known in the art or using a method disclosed in Remington's Pharmaceutical Science (Recent Edition), Mack Publishing Company, Easton PA. Can be formulated.

The dosage of the oral hygiene composition according to the present invention may be appropriately selected by a person skilled in the art in consideration of the administration method, the age, sex and weight of the patient, and the severity of the disease. In one example, the oral hygiene composition of the present invention, 2-methoxycinnamaldehyde, can be administered as 0.0001 mg / kg to 1000 mg / kg, 0.01 mg / kg to 100 mg / kg to be more effective. The administration may be administered once a day, or may be divided into several times. The above dosage does not limit the scope of the present invention in any way.

In addition, the oral hygiene composition of the present invention may further include a compound or a plant extract having a known oral disease inhibitory activity in addition to the active ingredient, and the content may be determined differently according to the production method and purpose of use.

The present invention provides an oral hygiene composition for preventing or ameliorating oral diseases comprising at least one of eugenol and hinokitiol and carbazochrom as an active ingredient, which includes all types and formulations that can be used for oral hygiene. do. Accordingly, non-limiting examples of the oral hygiene composition include food compositions and pharmaceutical compositions (including quasi-drug compositions), specifically, toothpaste, mouthwash, oral spray, oral ointment, gum, and the like.

The present invention also provides a food composition for preventing or improving oral diseases comprising at least one of eugenol and hinokithiol and carbazochrome as active ingredients. Examples of the food composition of the present invention include food, food additives, beverages or beverage additives.

In one aspect of the present invention, in the food composition, carbazochrome is included in 0.001 to 0.1% by weight, and any one or more of eugenol and hinokitiol may be included in 0.001 to 0.1% by weight. Specifically, 0.001 to 0.05% by weight of carbazochrome, 0.001 to 0.05% by weight of eugenol or hinokitiol may be included, and more specifically 0.003 to 0.01% by weight of carbazochrome, 0.003 to 0.01% by weight of eugenol or hinokitiol may be included, , More specifically, it may include 0.003 to 0.007% by weight of carbazochrome, 0.003 to 0.007% by weight of eugenol or hinokitiol.

In the food composition of the present invention, the content of carbazochrom and the content of any one or more of eugenol and hinokitiol may be the same or different, and in different cases, one or more of eugenol and hinokitiol compared to the content of carbazochrom The content may be 50 to 150%.

Food composition of the present invention is any one selected from the group consisting of bad breath, acute, dental caries, periodontal disease, gingivitis, periodontitis, pulpitis, stomatitis, oral mucositis, mucosal ulcers in the oral cavity, thrush, lichen planus and other oral inflammatory lesions It can exert prevention and improvement effects on the above diseases.

The food composition of the present invention may further include suitable carriers, excipients, and diluents commonly used in its manufacture.

As used herein, the term “food” refers to a natural product or a processed product that contains one or more nutrients, and preferably means a state that can be directly eaten after some processing process, and is usually used. By phosphorus, it includes food, food additives, functional food and beverages.

Foods that may contain the active ingredients of the present invention include, for example, various foods, beverages, chewing gum, candy, tea, vitamin complexes, functional foods, and the like. In addition, in the present invention, foods include special nutritional foods (e.g., formulas, infants, infant foods, etc.), processed meat products, fish meat products, tofu, jelly, noodles (e.g. ramen, noodles, etc.), health supplements, seasoned foods ( Yes, soy sauce, miso, red pepper paste, mixed sauce, etc., sauces, confectionery (e.g., snacks), dairy products (e.g. fermented milk, cheese, etc.), other processed foods, kimchi, pickled foods (various kimchi, pickles, etc.), beverages ( Examples include, but are not limited to, fruit, vegetable beverages, soy milk, fermented beverages, ice cream, etc., natural seasonings (e.g., ramen soup, etc.), vitamin complexes, alcoholic beverages, alcoholic beverages, and other health supplements. The food, beverage or food additive may be prepared by a conventional manufacturing method.

As used herein, the term “functional food” refers to a bio-defense rhythm of a food group or food composition that provides added value to act and express the function of a food for a specific purpose by using physical, biochemical, or biotechnological techniques Refers to a food product designed and processed to sufficiently express the body control functions related to regulation, disease prevention and recovery, and the functional food of the present invention preferably provides a body control function related to the prevention or improvement of oral diseases to the living body. It means food that can express sufficiently. The functional food may include a food-acceptable food supplement additive, and may further include suitable carriers, excipients, and diluents commonly used in the production of functional foods.

As used herein, the term "beverage" refers to the generic term for drinking to relieve thirst or to enjoy the taste and is intended to include functional beverages. The beverage is an essential component in the indicated proportions, and there are no particular restrictions on other components other than the active component, and may contain various flavoring agents or natural carbohydrates, etc., as additional components, as in conventional beverages. Examples of such natural carbohydrates include monosaccharides, such as disaccharides such as glucose and fructose, such as maltose, sucrose, etc., and polysaccharides, such as conventional sugars such as dextrin, cyclodextrin, and the like. Sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents other than those described above, natural flavoring agents (taumatine, stevia extract (for example, rebaudioside A, glycyrrhizine, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used. The ratio of the natural carbohydrate is generally about 1 to 20 g, preferably 5 to 12 g per 100 ml of the composition of the present invention.Other compositions of the present invention are flesh for the preparation of natural fruit juice, fruit juice beverage, and vegetable beverage. It may further contain.

In addition to the above, the composition of the present invention includes various nutrients, vitamins, minerals (electrolytes), flavoring agents such as synthetic flavoring agents and natural flavoring agents, coloring agents and neutralizing agents (cheese, chocolate, etc.), pectic acid and salts thereof, alginic acid and the like. It may contain salts, organic acids, protective colloidal thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohol, carbonic acid used in carbonated beverages, and the like. These components can be used independently or in combination.

As used herein, the term “functional beverage” refers to a biological defense of a beverage group or beverage composition that gives added value to act and express the function of the beverage for a specific purpose by using physical, biochemical, or biotechnological techniques on the beverage. It means a beverage that has been designed and designed to sufficiently express the body's control functions for rhythm control, disease prevention and recovery, etc.

The functional beverage is an essential component in the indicated proportions, and there is no particular limitation on other components other than the one containing the 2-methoxycinnamaldehyde of the present invention, and contains various flavors or natural carbohydrates, etc. as additional components, such as ordinary beverages. can do. Examples of such natural carbohydrates include monosaccharides, such as disaccharides such as glucose and fructose, such as maltose, sucrose, and polysaccharides, such as conventional sugars such as dextrin, cyclodextrin, and xylitol. , Sugar alcohols such as sorbitol and erythritol. As flavoring agents other than those described above, natural flavoring agents (taumatine, stevia extract (for example, rebaudioside A, glycyrrhizine, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used. .

The present invention also provides a pharmaceutical composition for the prevention, improvement or treatment of oral diseases comprising at least one of eugenol and hinokitiol and carbazochrom as active ingredients.

In one aspect of the present invention, carbazochrome is included in the pharmaceutical composition of the present invention in an amount of 0.001 to 0.1% by weight, and any one or more of eugenol and hinokitiol may be included in an amount of 0.001 to 0.1% by weight. Specifically, 0.001 to 0.05% by weight of carbazochrome, 0.001 to 0.05% by weight of eugenol or hinokitiol may be included, and more specifically 0.003 to 0.01% by weight of carbazochrome, 0.003 to 0.01% by weight of eugenol or hinokitiol may be included, , More specifically, it may include 0.003 to 0.007% by weight of carbazochrome, 0.003 to 0.007% by weight of eugenol or hinokitiol.

In the pharmaceutical composition of the present invention, the content of carbazochrom and the content of any one or more of eugenol and hinokitiol may be the same or different, and in different cases, one or more of eugenol and hinokitiol compared to the content of carbazochrom The content may be 50 to 150%.

The pharmaceutical composition of the present invention is any one selected from the group consisting of bad breath, acute teeth, dental caries, periodontal disease, gingivitis, periodontitis, pulpitis, stomatitis, oral mucositis, mucosal ulcers in the oral cavity, thrush, lichen planus and other oral inflammatory lesions It is possible to exert a prevention, improvement and treatment effect on the above diseases.

The method for preparing a pharmaceutical composition for treating or preventing oral disease of the present invention may be prepared according to a method conventionally manufactured in the industry for manufacturing the same.

The oral composition of the present invention, in addition to the active ingredient, as a component in general according to the formulation and purpose of use, we may further include a wetting agent, abrasive, drug, sweetener, pH adjusting agent, preservatives, binders, flavoring agents, foaming agents, etc. .

Wetting agents are used alone or in a mixture of concentrated glycerin, glycerin, sorbitol aqueous solution, amorphous sorbitol aqueous solution, polyethylene glycols and propylene glycol, and the amount used is 1 to 70% by weight based on the total weight of the oral composition.

Abrasives are selected from the group consisting of precipitated silica, silica gel, zirconium silicate, calcium monohydrogen phosphate, calcium monohydrogen phosphate, hydrous alumina, light calcium carbonate, heavy calcium carbonate, calcium pyrophosphate, insoluble metaphosphate, and aluminum silicate. Etc. can be used. The amount of the abrasive is generally 1 to 60% by weight based on the total weight of the oral composition. In addition, additives used in small amounts may include sweeteners, pH adjusters, preservatives, colorants, and binders as commonly used components.

Sodium fluoride, sodium monofluorophosphate, sodium fluoride, tin fluoride, chlorohexidine, allantoin chlorohydroxyaluminate, aminocaproic acid, zinc chloride, pyridoxine hydrochloride, tocopherol acetate, enzymes, etc. It can be used by mixing above. As a sweetener, saccharin, xylitol, erythritol, aspartame, or the like can be used, and the amount of the sweetener is usually 0.05 to 2% by weight based on the total weight of the oral composition.

As the pH adjusting agent, sodium phosphate, disodium phosphate, citric acid, triethanolamine, and the like can be used. As a preservative, benzoic acid, methylparaben, propylparaben, sodium benzoate, and the like can be used. As a fragrance, peppermint oil, spearmint oil, menthol, etc. are used in combination.

As other additives, enzymes such as dextranase may be used. As the binder, carrageenan, xanthan gum, sodium carboxy methyl cellulose, carboxy vinyl polymer, sodium alginate, laponite, or the like can be used alone or in combination of two or more. As the foaming agent, anionic surfactant sodium lauryl sulfate, copolymer of nonionic surfactant polyoxyethylene polyoxypropylene (poloxamer), polyoxyethylene cured castor oil, polyoxyethylene sorbitan fatty acid ester, etc. may be used. . In addition, it may contain a residual amount of water.

According to another embodiment of the present invention, there is provided an oral hygiene product comprising the composition. The composition for oral hygiene according to the present invention is a composition for oral hygiene that can be generally included in products manufactured and marketed for oral health, and the oral hygiene products applied are not limited. For example, the oral hygiene products include, but are not limited to, toothpaste, oral spray, oral ointment, oral patch, and mouthwash. The product for oral hygiene of the present invention may be in a liquid, solid, suspension, gel, or aerosol form, but is not limited thereto.

When the oral hygiene composition of the present invention is a toothpaste, in addition to containing any one or more of eugenol and hinokitiol and carbazochrom as active ingredients, abrasives, caking agents, moisturizing agents, blowing agents, sweeteners, whitening agents or flavoring agents are added. It can contain as. The abrasives include aluminum hydroxide, silicic anhydride, aluminum silicate, dibasic calcium phosphate 2 anhydride and anhydride, tricalcium phosphate, calcium carbonate, calcium pyrophosphate, insoluble sodium metaphosphate, tribasic magnesium phosphate, magnesium carbonate, calcium sulfate, Polymethacrylate methyl or the like can be used alone or in combination. The content of the abrasive may be usually 20% by weight to 90% by weight based on the total composition, but is not limited by the content.

When the oral hygiene composition is a paste-like composition, the caking agent is a gum such as garagenin, various thickening cellulose derivatives, xanthan gum, tragacanth gum, polyvinyl alcohol, sodium polyacrylate, polyacrylic acid / An organic caking agent such as a maleic acid copolymer or a synthetic polymer derivative such as a carboxyvinyl polymer, and an inorganic caking agent such as silica or laponite may be used alone or in combination. The content of the caking agent may be usually 0.3% by weight to 5% by weight based on the total composition, but is not limited by the content.

In addition, the oral hygiene composition may further include sorbitol, glycerin, ethylene glycol, propylene glycol, polyether glycol, polypropylene glycol, etc. as a moisturizing agent during its preparation.

In addition, the oral hygiene composition may further include a fragrance or sweetener. The sweetener may be sucrose, lactose, maltose, sorbitol, xylitol, sodium cyclamate, glycerin, sodium saccharin, stevioside, aspartame, etc., and the fragrance may be peppermint, menthol, anethol, eugenol, Limonene, citronenol, alpha terpineol, salicylmethyl, cineol, linarol, ethylinarol, vanillin, thymol, spearmint oil, sesame oil, rosemary oil, cinnamon oil, etc., the sweetener or fragrance alone It can be used as or in combination.

In addition, the oral hygiene composition of the present invention may include a surfactant or an additional efficacy component used alone or in combination as a foaming component. The surfactant used as the foaming component may be any one selected from the group consisting of anionic surfactants, nonionic surfactants and cationic surfactants.

When the oral hygiene composition of the present invention is a toothpaste, it can be prepared by a conventional toothpaste manufacturing method except for including the active ingredient, and when the oral hygiene composition of the present invention is a fern solution, in a conventional solution. It can be prepared by mixing 2-methoxycinnamaldehyde and formulated with a fern solution, and can prevent or treat oral diseases by washing the mouth 2 to 10 times a day.

In addition, when the oral hygiene composition of the present invention is a toothpaste cream, a liquid containing a water and a moisturizing agent, a gelling agent or a water-insoluble brightener, a sweetener, a fragrance, etc. may be further included.

In addition, when the oral hygiene composition of the present invention is a mouthwash (cleanser), it may further include a toothpaste carrier, more specifically, non-toxic alcohol.

Hereinafter, the present invention will be described in more detail through examples. However, these are only for explaining the present invention in more detail, and the scope of the present invention is not limited thereto.

[Example 1] Antibacterial effect experiment

Antibacterial activity test was conducted using a paper disc test to see if it had the effect of inhibiting strains using the dental caries and periodontal disease representative bacteria, Gram-positive bacteria Streptococcus mutans and Gram-negative bacteria Popiromonas gingivalis.

Each of the above bacteria, after cultivating the activity under the optimum culture conditions in Table 1, cultured for 4 to 6 hours in the optimum medium of each bacteria to increase the turbidity of the culture medium in Macfarland turbidity No. After adjusting to 0.5 (1.5x10 ⁸ ), 0.1 ml was spread evenly. Each material was inoculated at a concentration of 10 mg / disc on a sterile paper disk (Whatman no. 5 paper, 8 mm diameter), dried for absorption for 1 hour, and then used. After culturing for 24 to 48 hours at the optimum temperature of each of the bacteria, the size (diameter mm) of the growth inhibition ring was measured.

Strain Optimal condition Gram dyeing
(Gram staining) Strain name Temperature badge characteristics Gram (+) Streptococcus mutans 37 ℃ BHI Facultative anaerobic Gram (-) Porphyromonas gingivalis 37 ℃ TSA Hemin Menadione medium Anaerobic

The results are shown in the table below.

Processing material Growth inhibition diameter (mm) S.mutans P. gingivalis No treatment -
(No inhibition) -
(No inhibition) Eugenol alone 9.8 10.1 Hinokitiol alone 10.4 10.3 Carbazochrome sodium sulfonate (CSS) 9.5 9.6 Hinokitiol + CSS 11.0 11.7 Eugenol + CSS 11.5 11.6 Eugenol + Hinokitiol + CSS 12.4 12.3

[Example 2] PGE2 inhibitory effect

To confirm the effect of alleviating toothache and suppressing inflammation, the efficacy of inhibiting the pain and inflammation marker prostaglandin E2 (PGE2) was confirmed.

Macrophages were inoculated at a concentration of 1.5x10 ⁵ cells / ml in DMEM medium containing 10% fetal bovine serum (FBS) and cultured for 24 hours in a 24-well plate at 37 ° C and 5% CO ₂ conditions. In addition, 1 μg / ml of lipopolysaccharide (LPS), an inflammation-inducing stimulator, and each substance were treated with the composition shown in the table below to evaluate PGE2 inhibitory ability with the supernatant cultured for 24 hours.

Processing material Percentage (%) Standard Deviation No treatment 4 1.9 Lipopolysaccharide (LPS) 1 μg / ml 100 0.4 Eugenol 10 (0.01%) 30 0.5 Hinokitiol 10 (0.01%) 75 1.6 CSS (Carbazochrome Sodium Sulfonate) 10 (0.01%) 54 3.1 Eugenol 5 (0.005%) + CSS5 (0.005%) 17 2.7 Hinokitiol 5 (0.005%) + CSS5 (0.005%) 24 1.6 Eugenol 3 (0.0033%) + Hinokitiol 3 (0.0033%) + CSS3 (0.0033%) 10 0.4

The experimental results are shown in Table 1 and FIG. 1 above. It can be seen that the PGE2 inhibitory effect is superior when the CSS is combined with any one or more of the hinokithiol and eugenol than when the eugenol, hinokithiol, or CSS is treated alone, and the total concentration of the final effective substance is equal to 0.01%. In addition, the PGE2 inhibitory effect was excellent, and in particular, when all three substances were combined, the best PGE2 inhibitory ability was confirmed.

[Example 3] Inhibition effect of gingivitis

In order to compare the degree of inhibition of gingivitis, sodium carboxymethylcellulose, sodium lauryl sulfate, glycerin, colloidal silicon dioxide, silicas, sodium sodium sodium cochiol, sodium dodecine and sweetener, fragrances can be used. , A control toothpaste was prepared using a colorant, and the like, and an experimental group toothpaste containing each substance was prepared.

Control Contains sodium carboxymethylcellulose, sodium lauryl sulfate, glycerin, colloidal silicon dioxide, silicas, sodium cocoyl isethionate, dodecine and sweetener, fragrance, colorant Experiment group 1 Control + Eugenol 0.01% Experiment group 2 Control group + Hinokithiol 0.01% Experiment group 3 Control + CSS (carbazochromium sodium sulfonate) 0.01% Experimental group 4 Control + Hinokithiol 0.005% + CSS 0.005% Experimental group 5 Control + Eugenol 0.005% + CSS 0.005% Experimental group 6 Control + Eugenol 0.0033% + Hinokitiol 0.0033% + CSS 0.0033%

The subjects were gingivitis patients who had even dentition and no missing teeth. 30 subjects were selected from 30 to 50 years of age, followed by precise oral checkups by 30 people according to gender. Clinical trials were conducted on the effect of gingivitis treatment. The test group was divided into the experimental group and the control group, and was educated to use 3 times a day before going to sleep after 2 hours after eating, and the initial gingivitis index was scored by performing tooth smear, and each toothpaste composition was used for 1 week, 1 month, and 3 After months and 6 months, oral examinations were conducted to examine the gingivitis index. The method of measuring the gingivitis index is by inserting a periodontal probe into the gingival fissure, burning the probe around each tooth without applying force, and measuring the bleeding condition after 30 seconds, as shown in Table 5 below. The scores were recorded by the method to obtain the results in Table 6.

score Contents 0 points No bleeding condition 1 point Normal bleeding condition 2 points Hemorrhage on the ship 3 points Interstitial triangle bleeding condition 4 points Total gingival bleeding condition

group
time Control Experiment group 1 Experiment group 2 Experiment group 3 Experimental group 4 Experimental group 5 Experimental group 6 0 weeks 1.05 1.05 1.04 1.06 1.04 1.05 1.05 1 week 1.53 1.11 1.13 1.10 1.08 1.07 1.06 1 month 2.62 1.16 1.21 1.19 1.12 1.10 1.06 3 months 2.82 1.18 1.22 1.20 1.13 1.14 1.07 6 months 2.90 1.21 1.23 1.20 1.15 1.14 1.07

As a result of the above experiment, after 1 week, the level of inflammation of the control group was already the most severe at 1.53, and the inflammation was still worsened after 6 months, whereas the combination of the hinokithiol + CSS of the present invention (Experiment 4), the combination of eugenol + CSS ( Experimental group 5) and the combination of eugenol + hinokitiol + CSS (experimental group 6), compared to the control group as well as eugenol alone (experimental group 1), hinokitiol alone (experimental group 2) or CSS alone (experimental group 3). It was confirmed that the degree of inflammation was low throughout.

[Example 4] Comparison of the degree of suppression of syrin

In order to compare the degree of suppression of sirin, sodium carboxymethylcellulose, sodium lauryl sulfate, glycerin, colloidal silicon dioxide, silicas, sodium sodium sodium sodium cochiol, dodecine and sweetener, fragrance, A control toothpaste was made using a colorant or the like, and an experimental group toothpaste containing each substance was prepared therein. (See Table 3)

The degree of suppression of the symptoms of the syrin of the compositions prepared above was comparatively measured. In other words, 40 volunteers who agreed to participate in this experiment as subjects with perceptual hypersensitivity teeth were included in the study, and a total of 80 teeth were studied.

In addition, there were 20 men and 20 women among the applicants, and the age ranged from 20 to 50 years. The subjects were not allowed to know the contents of the toothpaste, and the total test period was 2 weeks.

The test was conducted by measuring the patient's response after applying temperature stimulation. Before conducting the test, the hypersensitivity area of each candidate's perceptive hypersensitivity teeth was checked beforehand, and each drop of cold water at a temperature of about 5 ° C. was dropped into a dropper of the tooth with a dropper for evaluation, and each composition was used 3 times a day for 2 weeks. After 2 weeks, the water was dropped again to a dropper of about 5 ° C with a dropper for evaluation. After stimulation, the criteria for the patient's response rating were set as follows. (0 points: no discomfort. 1 point: slightly uncomfortable or cold, 3 points: sick). Statistical treatment was tested by paired student-t test for stimulation scores before and 2 weeks after laboratory.

The response scores for temperature stimuli after 2 weeks are shown in Table 7 below.

The degree of suppression group
time Control Experiment group 1 Experiment group 2 Experiment group 3 Experimental group 4 Experimental group 5 Experimental group 6 0 weeks 2.15 ± 0.10 2.15 ± 0.07 2.14 ± 0.11 2.13 ± 0.12 2.14 ± 0.05 2.15 ± 0.06 2.13 ± 0.06 2 weeks 2.15 ± 0.09 1.76 ± 0.11 1.70 ± 0.09 1.87 ± 0.02 1.60 ± 0.01 1.58 ± 0.12 1.53 ± 0.12 valence p> 0.05 * p <0.05 * p <0.05 * p <0.05 * p <0.05 * p <0.05 * p <0.05

As a result of the above experiment, the degree of stimulation of the control group was still 2.15 even after 2 weeks, but there was no significant decrease, whereas the hinokitiol + CSS combination (Experiment 4) of the present invention was from 2.14 to 1.60, and the combination of eugenol + CSS (Experiment 5) The stimulation decreased from 2.15 to 1.58, and the combination of eugenol + hinokitiol + CSS (Experimental group 6) from 2.13 to 1.53, all of which were statistically significant decreases from Week 0 results. It was confirmed that both hinokithiol alone (experimental group 2) or CSS alone (experimental group 3) were significantly reduced.

[Example 5] Bad breath removal effect experiment

To compare the degree of bad breath removal, sodium carboxymethylcellulose, sodium lauryl sulfate, glycerin, colloidal silicon dioxide, silicas, sodium sodium sodium cochiol, sodium dodecine and sweetener, fragrance, colorant A control toothpaste was prepared using a back, and an experimental group toothpaste containing each substance was prepared therein. (See Table 3)

50 men and women without dental caries were selected, and a cross-over test was performed on the target beverage. The commercial garlic powder was dispersed in water, allowed to stand for 24 hours, and then diluted, so that the measured value of the Harimeter was 700 ppb or more, and the diluted solution was used as a bad breath inducer. Gargles were diluted with 15 ml of garlic powder for 30 seconds, and after 1 minute, bad breath was measured with a halimeter, and then brushed for 30 seconds to 1 minute using a control group or a test group toothpaste. After 1 minute, 5 minutes, and 30 minutes of brushing teeth, the degree of bad breath was measured with a halimeter to measure whether or not to suppress bad breath. The results are shown in Table 8 below.

Bad breath removal effect group
time Control Experiment group 1 Experiment group 2 Experiment group 3 Experimental group 4 Experimental group 5 Experimental group 6 1 min 56.4% 96.0% 96.3% 81.0% 97.0% 97.1% 98.0% 5 minutes 46.8% 87.2% 88.6% 72.5% 92.2% 91.7% 95.1% 30 minutes 38.1% 83.1% 85.2% 70.0% 89.9% 90.4% 93.8%

As a result of the experiment, the bad breath suppression of the control group was 38.1% based on the 30 minutes of the experiment, whereas the hinokitiol + CSS combination (Experiment 4) of the present invention was 89.9%, the eugenol + CSS combination (Experiment 5) was 90.4%, and Eugenol + hinokithiol + CSS combination (Experimental group 6) was 93.8%, showing an excellent bad breath reduction effect, which is a very good bad breath reduction compared to the control group, as well as eugenol alone (Experiment 1), which stayed at about 70 to 83% It was confirmed that it was reduced compared to the case where the thiol alone (Experiment 2) or CSS alone (Experiment 3) was treated.

Through the above experiments, it can be confirmed that the composition of the present invention has a certain effect as a test composition for effectively maintaining and improving oral health by alleviating toothache, preventing or improving tooth caries, preventing or improving gum disease, bad breath, and reducing the symptoms of odor. have.

In the above, the applicant has described the preferred embodiments of the present invention, but these embodiments are only one embodiment for implementing the technical concept of the present invention and any modification or modification of the present invention as long as the technical concept of the present invention is implemented It should be construed as being within the scope.

Claims (12)

Oral hygiene composition for the prevention or improvement of oral diseases comprising at least one of eugenol and hinokithiol and carbazochrome as active ingredients. The oral hygiene composition according to claim 1, wherein the carbazochrome is carbazochrome sodium sulfonate. The oral hygiene composition of claim 1, wherein the carbazochrome is included in an amount of 0.001 to 0.1% by weight, and any one or more of eugenol and hinokitiol is included in an amount of 0.001 to 0.1% by weight. According to claim 1, wherein the oral disease is bad breath, acute teeth, dental caries, periodontal disease, gingivitis, periodontitis, pulpitis, stomatitis, oral mucositis, oral mucosal ulcers, thrush, squamous lichen and other oral inflammation lesions Oral hygiene composition, characterized in that any one or more diseases selected. The oral hygiene composition according to claim 1, wherein the composition has an antibacterial effect on a strain of the genus Streptococcus or a genus of Porphyromonas . The method of claim 5, wherein the Streptococcus ( Streptococcus ) strain or the strain of the genus Porphyromonas ( Streptococcus mutans ), Streptococcus sanggu ( Streptococcus sanguis ), Streptococcus sanguinis ( Streptococcus sanguinis ) , Streptococcus salivarius subsp. Thermophils , and oral hygiene composition, characterized in that at least one selected from the group consisting of Porphyromonas gingivalis . A food composition for improving oral hygiene comprising at least one of eugenol and hinokithiol and carbazochrome as active ingredients. The food composition for improving oral hygiene according to claim 7, wherein the carbazochrome is contained in an amount of 0.001 to 0.1% by weight, and any one or more of eugenol and hinokitiol is included in an amount of 0.001 to 0.1% by weight. The method according to claim 7, wherein the food composition is in the group consisting of bad breath, acute teeth, dental caries, periodontal disease, gingivitis, periodontitis, pulpitis, stomatitis, oral mucositis, oral mucosal ulcers, thrush, squamous lichen and other oral inflammation lesions A food composition for improving oral hygiene, characterized in that it prevents or improves any one or more diseases selected. A pharmaceutical composition for the prevention, amelioration or treatment of oral diseases comprising at least one of eugenol and hinokithiol and carbazochrome as active ingredients. The pharmaceutical composition of claim 10, wherein the carbazochrome is included in an amount of 0.001 to 0.1% by weight, and any one or more of eugenol and hinokitiol is included in an amount of 0.001 to 0.1% by weight. The method of claim 10, wherein the oral disease is bad breath, acute teeth, dental caries, periodontal disease, gingivitis, periodontitis, pulpitis, stomatitis, oral mucositis, oral mucosal ulcers, thrush, lichen planus and other oral inflammation lesions Pharmaceutical composition characterized in that it is any one or more diseases selected.

Images